Protagonist Therapeutics, Inc. (PTGX)

Market Cap	1.61B
Revenue (ttm)	859,000
Net Income (ttm)	-140.19M
Shares Out	57.25M
EPS (ttm)	-2.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	725,404
Open	27.58
Previous Close	27.49
Day's Range	27.24 - 28.26
52-Week Range	6.91 - 28.26
Beta	1.95
Analysts	Strong Buy
Price Target	33.00 (+17.02%)
Earnings Date	May 4, 2023

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinica...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2016
• Employees: 103
• Stock Exchange: NASDAQ
• Ticker Symbol: PTGX

Financial Performance

In 2022, PTGX's revenue was $26.58 million, a decrease of -2.84% compared to the previous year's $27.36 million. Losses were -$127.39 million, 1.47% more than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $33.0, which is an increase of 17.02% from the latest price.

Price Target

$33.0

(17.02% upside)

Analyst Consensus: Strong Buy